Large cell differentiation of metastatic prostate cancer after androgen deprivation therapy

被引：1

作者：

Patel, Rutveej ^{[1
]}

Faiena, Izak ^{[1
]}

Geltzeiler, Jules ^{[2
]}

机构：

[1] Rutgers Robert Wood Johnson Med Sch, Div Urol, New Brunswick, NJ USA

[2] Jersey Shore Univ, Med Ctr, Div Urol, Neptune, NJ USA

来源：

CANADIAN JOURNAL OF UROLOGY | 2015年 / 22卷 / 02期

关键词：

large cell neuroendocrine tumor; prostate cancer; hormone refractory prostate cancer; neuroendocrine differentiation; NEUROENDOCRINE DIFFERENTIATION;

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

We present a case of a 75-year-old male with a history of high risk prostate cancer who underwent androgen deprivation therapy and palliative radiation treatments for his disease. Subsequently, he presented with gross hematuria and severe lower urinary tract symptoms. A palliative transurethral resection of the prostate (TURP) at that time, demonstrated large cell differentiated neuroendocrine carcinoma with metastasis to the lung. We review the limited literature on this rare form of disease and present current treatment strategies.

引用

页码：7752 / 7754

页数：3

共 11 条

[1]

Ahlgren G, 2000, PROSTATE, V42, P274, DOI 10.1002/(SICI)1097-0045(20000301)42:4<274::AID-PROS4>3.0.CO

[2]

2-R

[3]

[Anonymous], J UROL

[4]

Azad Arun A, 2014, Clin Genitourin Cancer, V12, pe151, DOI 10.1016/j.clgc.2014.03.006

[5] Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma [J].

Cussenot, O ;

Villette, JM ;

Valeri, A ;

Cariou, G ;

Desgrandchamps, F ;

Cortesse, A ;

Meria, P ;

Teillac, P ;

Fiet, J ;

LeDuc, A .

JOURNAL OF UROLOGY, 1996, 155 (04) :1340-1343

[6] Large cell neuroendocrine carcinoma of prostate - A clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer [J].

Evans, AJ ;

Humphrey, PA ;

Belani, J ;

van der Kwast, TH ;

Srigley, JR .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (06) :684-693

[7] Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial [J].

Flechon, A. ;

Pouessel, D. ;

Ferlay, C. ;

Perol, D. ;

Beuzeboc, P. ;

Gravis, G. ;

Joly, F. ;

Oudard, S. ;

Deplanque, G. ;

Zanetta, S. ;

Fargeot, P. ;

Priou, F. ;

Droz, J. P. ;

Culine, S. .

ANNALS OF ONCOLOGY, 2011, 22 (11) :2476-2481

[8] Cancer statistics, 2007 [J].

Jemal, Ahmedin ;

Siegel, Rebecca ;

Ward, Elizabeth ;

Murray, Taylor ;

Xu, Jiaquan ;

Thun, Michael J. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) :43-66

[9] Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer [J].

Noda, W ;

Nishiwaki, Y ;

Kawahara, M ;

Negoro, S ;

Sugiura, T ;

Yokoyama, A ;

Fukuoka, M ;

Mori, K ;

Watanabe, K ;

Tamura, T ;

Yamamoto, S ;

Saijo, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02) :85-91

[10]

Sun Y, 2009, AM J TRANSL RES, V1, P148

← 1 2 →